NPS+ Haemophilia B (US) 2018 - Of the 7 Brands Included in the Survey, Only 3 Achieve a Positive NPS - ResearchAndMarkets.com

The "NPS+ Haemophilia B (US) 2018" report has been added to ResearchAndMarkets.com's offering.

There are various options available to US haematologists treating haemophilia B. Clearly some of these options are achieving greater levels of loyalty and satisfaction than others - but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?

NPS+ Haemophilia B (US) gives a unique insight into the overall brand health of 7 leading treatments for Haemophilia B currently being used in North America. 100 haematologists were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out.

Insight into 7 Haemophilia B Treatments

• Alprolix (eftrenonacog alfa; Bioverativ)
• BeneFIX (nonacog alfa; Pfizer)
• Feiba (Anti-Inhibitor Coagulant Complex; Shire)
• Idelvion (albutrepenonacog alfa; CSL Behring)
• MonoNine (Coagulation Factor IX (human); CSL Behring)
• Rixubis (nonacog gamma; Shire)
• Rebinyn (nonacog beta pegol; Novo Nordisk)

Key Takeaways

• Positive NPS are a scarce commodity. Of the 7 brands included in the survey, only three achieve a positive NPS...but only just. Which brand leads the pack and which ones are propping up the table?
• Loyalty is proving difficult to achieve. Loyalty scores of 4 or more are what brands are aiming for, but for Haemophilia B treatments, even the highest scores are not even close in this latest survey. Is clinical differentiation really that low?
• Despite low loyalty, satisfaction is pretty good. Why are haematologists so happy with the numerous drugs on offer? And is there any more that could be done to improve satisfaction scores even more?
• Marketing messaging could be the key. Which brands are associated with key issues such as safety, efficacy, convenient administration and cost effectiveness? Could more be done to promote key benefits?
• In their own words. What do doctors say each brand means to them? For example, which brand is described as a great medicine, well tolerated' and which brand is useful but very expensive'?

NPS+ Haemophilia B (US) offers valuable insight into brand loyalty from the perspective of those currently prescribing treatments for Haemophilia B to patients.

You'll discover:

• Exactly how satisfied the US market is.
• How loyal doctors are to your brand.
• How many other brands your Promoters recommend.
• Which other brands your Promoters and Detractors recommend.
• How much market share your brand has among Promoters and Detractors.
• How much market share you stand to gain by converting Detractors into Promoters.
• Which messages Promoters, Passives and Detractors associate with your brand.
• Your brand DNA: what doctors really think of your brandin their own words.

How does NPS work?

NPS measures overall brand satisfaction and loyalty by asking one simple question: "How likely are you to recommend this brand to a colleague?"

Responses, given on a scale of 0 (not at all likely) to 10 (extremely likely) are used to classify respondents into 3 categories:

• Detractors are those who answer 0 - 6
• Passives are those who answer 7 - 8
• Promoters are those who answer 9 -10

What is FirstView NPS+?

NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.

Each NPS+ report examines doctors' relationships with the brands used to treat a major disease areameasuring brand loyalty and showing you how it affects your market share. NPS+ also examines brand DNA, revealing in doctors' own words what brands mean to them.

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

Companies Featured

• Bioverativ
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire

Table of Contents

Chart 1: Net Promoter Score?

Chart 2: How loyal are doctors to my brand?

Chart 3: How satisfied is the market?

Chart 4: How many other brands are promoted by my Promoters?

Chart 5: Which other brand is most promoted by my Promoters?

Chart 6: Which other brands are promoted by my Detractors?

Chart 7: What is my brand's market share among Promoters and Detractors?

Chart 8: What brand messages are associated with Promoters, Passives and Detractors (by brand)?

Chart 9: What does my brand represent to Promoters and Detractors (by brand)?

For more information about this report visit https://www.researchandmarkets.com/research/vlhzl4/nps_haemophilia?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180718005841/en/